Human glucose-dependent insulinotropic polypeptide receptor (GIPR) antibodies and methods of use thereof to inhibit GIP receptor and signaling
AssigneeCrystal Bioscience Inc.
InventorsShelley Izquierdo, Shreya Pramanick, William Don Harriman
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies that specifically bind to and in some cases inhibit the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. For example, the antibodies may be used to treat a metabolic disorder, such as a disorder of glucose metabolism. In some embodiments, the antibody may have CDRs that are selected from any of the antibodies set forth in FIG. 9 or 10.
Claims16
An antibody that binds to the human glucose-dependent insulinotropic polypeptide (GIP) receptor, wherein the antibody comprises:
- a variable domain comprising:
- i. heavy chain CDR1, CDR2 and CDR3 regions that are identical to the heavy chain CDR1, CDR2 and CDR3 regions of an antibody selected from FIG. 9;
- and
- ii. light chain CDR1, CDR2 and CDR3 regions that are identical to the light chain CDR1, CDR2 and CDR3 regions of the antibody, selected from FIG. 10.
Dependencies are inferred from the claim text.